Compare SUJA & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUJA | BCYC |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.3M | 256.5M |
| IPO Year | 2026 | 2019 |
| Metric | SUJA | BCYC |
|---|---|---|
| Price | $6.38 | $3.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $12.40 | $9.17 |
| AVG Volume (30 Days) | 170.5K | ★ 378.8K |
| Earning Date | 11-10-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.99 | N/A |
| Revenue Next Year | $7.41 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.59 | $3.07 |
| 52 Week High | $12.42 | $7.83 |
| Indicator | SUJA | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 23.71 | 33.35 |
| Support Level | $5.59 | N/A |
| Resistance Level | $10.96 | $3.94 |
| Average True Range (ATR) | 0.79 | 0.18 |
| MACD | -0.45 | -0.06 |
| Stochastic Oscillator | 5.20 | 2.52 |
Suja Life Inc operates a beverage platform focused on producing and selling products such as cold-pressed juices, wellness shots, and functional sodas. Its portfolio includes brands such as Suja Organic, Vive Organic, and Slice. The Company operates and manages its business in two operating segments, which are also reportable segments: i) Suja Core: It produces and distributes cold-pressed fresh juice and cold-pressed juice shots. ii) Emerging Brands: It consists of recently acquired or launched brands and products that are still in the early stages of revenue scale, market development, or distribution build-out. The majority of revenue is derived from Suja Core.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.